Cargando…

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension

Patients with connective tissue disease-associated pulmonary arterial hypertension (PAH-CTD) have a poor prognosis compared with other aetiologies. The underlying CTD can influence treatment response and outcomes. We characterised the GRIPHON study PAH-CTD subgroup and evaluated response to selexipa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaine, Sean, Chin, Kelly, Coghlan, Gerry, Channick, Richard, Di Scala, Lilla, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Lang, Irene M., McLaughlin, Vallerie, Preiss, Ralph, Rubin, Lewis J., Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F., Hoeper, Marius M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593379/ https://www.ncbi.nlm.nih.gov/pubmed/28818881 http://dx.doi.org/10.1183/13993003.02493-2016

Ejemplares similares

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
por: Coghlan, J. Gerry, et al.
Publicado: (2018)

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
por: Beghetti, Maurice, et al.
Publicado: (2019)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
por: Rosenkranz, Stephan, et al.
Publicado: (2021)

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study
por: Chin, Kelly M., et al.
Publicado: (2019)

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension
por: Coghlan, J. Gerry, et al.
Publicado: (2023)

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
por: Galiè, Nazzareno, et al.
Publicado: (2021)

Future perspectives in pulmonary arterial hypertension
por: Simonneau, Gérald, et al.
Publicado: (2016)

New horizons in pulmonary arterial hypertension management
por: McLaughlin, Vallerie, et al.
Publicado: (2014)

A paradigm shift in pulmonary arterial hypertension management
por: Rubin, Lewis J., et al.
Publicado: (2013)

An overview of the 6th World Symposium on Pulmonary Hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Improving patient outcomes in pulmonary hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2015)

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
por: Coghlan, John Gerry, et al.
Publicado: (2017)

New horizons in pulmonary arterial hypertension therapies
por: Galiè, Nazzareno, et al.
Publicado: (2013)

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
por: Simonneau, Gérald, et al.
Publicado: (2015)

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial
por: Souza, Rogério, et al.
Publicado: (2018)

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2017)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Pulmonary arterial hypertension: tailoring treatment to risk in the current era
por: Gaine, Sean, et al.
Publicado: (2017)

Using a knowledge translation program to facilitate guideline‐ and evidence‐based patient management: the PAH‐QuERI Extension Program
por: McLaughlin, Vallerie V., et al.
Publicado: (2022)

Medical management of chronic thromboembolic pulmonary hypertension
por: Pepke-Zaba, Joanna, et al.
Publicado: (2017)

TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
por: Frantz, Robert P., et al.
Publicado: (2021)

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
por: Simonneau, Gérald, et al.
Publicado: (2020)

Risk stratification and medical therapy of pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
por: Souza, Rogério, et al.
Publicado: (2022)

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
por: White, R. James, et al.
Publicado: (2019)

Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases: Insights From Pulmonary Arterial Hypertension
por: Torbicki, Adam, et al.
Publicado: (2019)

Selexipag for pulmonary arterial hypertension
Publicado: (2021)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
por: Humbert, Marc, et al.
Publicado: (2023)

Quality of life in patients with chronic thromboembolic pulmonary hypertension
por: Mathai, Stephen C., et al.
Publicado: (2016)

The revised definition of pulmonary hypertension: exploring the impact on patient management
por: Simonneau, Gérald, et al.
Publicado: (2019)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries
por: Khanna, Dinesh, et al.
Publicado: (2021)

AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study
por: Gillies, Hunter, et al.
Publicado: (2023)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

The molecular targets of approved treatments for pulmonary arterial hypertension
por: Humbert, Marc, et al.
Publicado: (2016)

Modulating cGMP to Treat Lung Diseases
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2009)

The role of combination therapy in managing pulmonary arterial hypertension
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2014)

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
por: Rothman, Abraham, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_65cs6s6aijcnv54gasstj7iatn